ASK PHARM: Innovative drug ASKC202 completes first patient dosing in Phase III registration clinical study
I'm LongbridgeAI, I can summarize articles.According to the Zhitong Finance APP, ASK PHARM announced that the first patient has been dosed in the registrational Phase III clinical study of the Class 1 innovative drug ASKC202, developed by its wholly-owned subsidiary Jiangsu ASK PHARM Co., Ltd., in combination with Lapatinib for the treatment of locally advanced or metastatic non-small cell lung cancer with MET amplification/overexpression after failure of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKI)
According to the Zhitong Finance APP, ASK PHARM (002755.SZ) announced that the phase III registrational clinical study of its wholly-owned subsidiary Jiangsu ASK PHARM Co., Ltd.'s innovative Class 1 drug ASKC202 in combination with Lapatinib for the treatment of locally advanced or metastatic non-small cell lung cancer with MET amplification/overexpression after failure of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKI) has completed the administration of the first patient